Pfizer Inc. $PFE Shares Acquired by Lynx Investment Advisory

Key Points

• Lynx Investment Advisory has increased its stake in Pfizer by 53.3%, owning 47,782 shares valued at approximately $1.21 million.
• Pfizer reported a quarterly earnings per share of $0.78, surpassing estimates, and its revenue reached $14.65 billion, a 10.3% increase year-over-year.
• The company has declared a quarterly dividend of $0.43 per share, equating to an annual yield of 6.9%, with a payout ratio of 91.49%.

Lynx Investment Advisory boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 53.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,782 shares of the biopharmaceutical company's stock after purchasing an additional 16,621 shares during the quarter. Pfizer makes up approximately 0.8% of Lynx Investment Advisory's holdings, making the stock its 29th largest position. Lynx Investment Advisory's holdings in Pfizer were worth $1,211,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Gould Capital LLC boosted its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the 1st quarter valued at approximately $27,000. North Capital Inc. acquired a new position in Pfizer during the 1st quarter valued at approximately $28,000. Bayforest Capital Ltd acquired a new position in Pfizer during the 1st quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer during the 4th quarter valued at approximately $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Trading Up 1.1%

Shares of Pfizer stock opened at $24.84 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a market cap of $141.23 billion, a price-to-earnings ratio of 13.21, a price-to-earnings-growth ratio of 0.87 and a beta of 0.55. The business has a fifty day simple moving average of $24.82 and a 200-day simple moving average of $24.32. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer's dividend payout ratio is 91.49%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. HSBC reduced their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Morgan Stanley boosted their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Bank of America boosted their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Finally, Jefferies Financial Group boosted their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.